A remarkable therapeutic opportunity has been discovered recently for cancer patients that carry mutations of the familial breast cancer genes BRCA1 or BRCA2. Both genes play important roles in the HR repair pathway. This evidence concerns the gene BRCA1 and breast carcinoma.